Cambridge Investment Research Advisors Inc. Acquires 114 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Cambridge Investment Research Advisors Inc. grew its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Rating) by 2.2% in the 4th quarter, Holdings Channel reports. The fund owned 5,338 shares of the medical instruments supplier’s stock after purchasing an additional 114 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Mesa Laboratories were worth $887,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Geneva Capital Management LLC increased its position in shares of Mesa Laboratories by 83.1% during the fourth quarter. Geneva Capital Management LLC now owns 191,816 shares of the medical instruments supplier’s stock worth $31,882,000 after acquiring an additional 87,031 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in shares of Mesa Laboratories by 17.8% during the fourth quarter. Conestoga Capital Advisors LLC now owns 574,783 shares of the medical instruments supplier’s stock worth $95,535,000 after acquiring an additional 86,648 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Mesa Laboratories during the third quarter worth $5,092,000. Citadel Advisors LLC grew its holdings in shares of Mesa Laboratories by 384.3% during the third quarter. Citadel Advisors LLC now owns 22,281 shares of the medical instruments supplier’s stock worth $3,138,000 after buying an additional 17,680 shares in the last quarter. Finally, Eagle Asset Management Inc. grew its holdings in shares of Mesa Laboratories by 18.9% during the third quarter. Eagle Asset Management Inc. now owns 89,979 shares of the medical instruments supplier’s stock worth $12,671,000 after buying an additional 14,303 shares in the last quarter. 93.00% of the stock is currently owned by institutional investors.

Insider Activity at Mesa Laboratories

In related news, CFO John Sakys sold 2,128 shares of the stock in a transaction that occurred on Friday, March 24th. The stock was sold at an average price of $167.01, for a total transaction of $355,397.28. Following the completion of the transaction, the chief financial officer now directly owns 9,696 shares of the company’s stock, valued at $1,619,328.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 6,028 shares of company stock valued at $1,018,145. 5.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Mesa Laboratories in a report on Thursday. They set a “hold” rating for the company.

Mesa Laboratories Stock Up 0.5 %

Mesa Laboratories stock opened at $158.70 on Friday. The company has a fifty day simple moving average of $167.91 and a 200 day simple moving average of $173.46. The company has a current ratio of 2.74, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. Mesa Laboratories, Inc. has a 1-year low of $114.21 and a 1-year high of $226.40. The company has a market cap of $849.05 million, a P/E ratio of -547.22 and a beta of 0.73.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Wednesday, May 31st will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Tuesday, May 30th. Mesa Laboratories’s payout ratio is -220.68%.

Mesa Laboratories Company Profile

(Get Rating)

Mesa Laboratories, Inc engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development.